drugset / Trial / NCT05322330
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2
Completed
20 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe Affiliated People's Hospital of Ningbo University · collabThe General Hospital of Western Theater Command · collabWest China Hospital · collabWuxi No. 2 People's Hospital · collabYixing People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma
Timeline
- Start
- 2022-02-10
- Primary completion
- 2024-02-10
- Completion
- 2024-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chimeric antigen receptor-modified T (CAR-T) cell therapy | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | Chimeric antigen receptor-modified T (CAR-T) cell therapy | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | CTX | Unknown | 250 mg/m2 | Intravenous |
| Background | CTX | Unknown | 500 mg/m2 | Intravenous |
| Background | Flu | Unknown | 25 mg/m2 | Intravenous |
| Background | Flu | Unknown | 30 mg/m2 | Intravenous |